This study reveals the core mechanism by which insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) drives tumor progression and radiotherapy resistance in gastric cancer (GC) through m6A-dependent regulation of hypoxia-inducible factor 1α (HIF1α). Clinical analyses show that IGF2BP2 is significantly overexpressed in gastric cancer tissues, and its expression level is closely associated with tumor size and poor patient prognosis. Functional studies demonstrate that elevated expression of IGF2BP2 accelerates the transition of gastric cancer cells from the G1 phase to the G2/M phase of the cell cycle and markedly enhances cell proliferation and migration through anti-apoptotic effects. Mechanistically, IGF2BP2 specifically binds to the m6A-modified “GGACU” motif within the coding region of HIF1α mRNA, positively regulating HIF1α mRNA stability and protein expression in an m6A-dependent manner. High IGF2BP2 expression significantly enhances glycolytic activity in gastric cancer cells, while overexpression of HIF1α partially rescues the suppression of malignant phenotypes caused by IGF2BP2 knockdown, indicating that HIF1α serves as a key downstream effector mediating the oncogenic role of IGF2BP2 in gastric cancer. Furthermore, knockdown of IGF2BP2 significantly increases radiosensitivity by exacerbating DNA damage and enhancing oxidative stress.
Numerous clinical studies indicate that neoadjuvant chemoradiotherapy (NCRT) with immunotherapy can significantly increase pathological complete response (pCR) and clinical complete response (cCR) rates to over 30-60%, substantially higher than the 15-20% observed with conventional NCRT. This allows more patients to become eligible for a Watch-and-Wait (WW) strategy, successfully preserving organ function. Several phase III randomized controlled trials (RCTs) are currently underway. The combination of NCRT and immunotherapy holds promise for breaking the therapeutic impasse in proficient mismatch repair/microsatellite stability (pMMR/MSS) rectal cancer, markedly enhancing tumor regression and the potential for organ preservation. However, challenges remain for NCRT combined with immunotherapy in this population. First of all, there is an unmet need to identify predictive biomarkers for treatment response in pMMR/MSS rectal cancer. Next, treatment protocols require further optimization, specifically in determining the best radiotherapy fractionation schedule, its sequencing with immunotherapy, and the radiotherapy target volume. Otherwise, the phenomenon of “pseudo-residual disease” complicates traditional radiological assessment of cCR and must be overcome. Furthermore, the long-term survival benefits of combining radiotherapy with immunotherapy need further confirmation. This review provided a comprehensive and in-depth view of immunotherapy-based NCRT (iNCRT) in patients with pMMR/MSS rectal cancer and discuss the new opportunities and challenges this strategy presents for achieving organ preservation.
To explore the effect of sodium dichloroacetate (DCA), a pyruvate dehydrogenase kinase (PDK) inhibitor, on the progression of gastric cancer and resistance to radiotherapy, we analyzed histopathological microarrays from 60 gastric cancer and paracancerous tissues to determine PDK expression and its prognostic significance. 5-Ethynyl-2′-deoxyuridine (EdU) incorporation assay and Transwell migration assay were used to investigate the effects of PDK inhibition on gastric cancer cell proliferation and migration. Flow cytometry revealed that PDK inhibition promoted apoptosis and induced G1 phase cell cycle arrest. Colony formation assay combined with radiation was performed to calculate radiobiological parameters, while Western blot detected the expression of phosphorylated histone H2AX (γ-H2AX), a DNA double-strand break marker. Reactive oxygen species (ROS) generation was measured using the fluorescent probe 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA). Our results showed that PDK was highly expressed in gastric cancer tissues and correlated with poor patient prognosis. PDK inhibition suppressed proliferation and migration of gastric cancer cells, promoted apoptosis and G1 phase arrest, and enhanced γ-H2AX accumulation and ROS generation, thereby increasing radiosensitivity. These findings demonstrate that targeting PDK inhibits gastric cancer progression and sensitizes tumor cells to radiotherapy.
Chemotherapy is regularly recommended for surgically rectal neuroendocrine carcinoma (NEC) patients. However, the additional benefit of perioperative radiotherapy for these patients is unclear to date. This study aims to evaluate the outcome of radiotherapy in rectal NECs who treated with surgery and chemotherapy. This is a retrospective controlled study based on SEER database. Propensity score matching (PSM) was applied to reduce the baseline bias. Rectal NECs who underwent surgical resection plus chemotherapy with or without radiotherapy were extracted from SEER database. According to whether receiving radiotherapy, patients were divided into two cohorts: radiation treatment (RT) group and non-RT group. Overall survival (OS) was measured to assess the clinical benefits of RT. Kaplan-Meier survival analysis, univariable and multivariable regression analysis were applied. A total of 666 eligible patients were finally enrolled. The difference in OS remained significant both before and after PSM. Subgroup analyses revealed significantly better results for stage II, III and even IV patients who received radiotherapy whether before or after matching (all p < 0.05). The multivariable analysis showed that radiotherapy was associated with OS (HR 0.54; 95% CI 0.45 to 0.65; p < 0.001), together with distant metastasis. These results were consistent after matching (both p < 0.05). Radiotherapy was an independent favorable prognostic factor for rectal NECs. The addition of radiotherapy to surgery plus chemotherapy might improve the clinical outcome. In the future, well-designed prospective studies are needed to assess the potential role of radiation in managing surgically resectable rectal NEC.
A correction refers to a change to their article that the author wishes to publish after publication. The publication of this article is subject to Frontiers' editorial approval. Instructions: ●Please read through all the templates before choosing ●Pick the most relevant text template(s) from the following page and delete all others. ●Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. ●Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary ●Submit to Frontiers following the instructions on this page. When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example: There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake. The original version of this article has been updated. In the published article, there was a mistake in the Funding statement. The funding statement for the Key Development Project of the Department of Science and Technology was displayed as "2015CBd051". The correct statement is "Key Development Project of Department of Science and Technology (2015C03Bd051).'' Correction: IGF2BP2 regulates gastric cancer radiotherapy resistance through HIF1a-mediated glycolysis
Fatty acid metabolism is a core metabolic pathway regulating tumor metastasis. Through fatty acid uptake and intracellular transport mediated by CD36 and fatty acid-binding proteins (FABPs), fatty acid oxidation (FAO) regulated by carnitine palmitoyltransferase 1 (CPT1), and fatty acid desaturation modification mediated by stearoyl-CoA desaturase 1 (SCD1) and fatty acid desaturase 2 (FADS2), it modulates the entire process of tumor cell invasion, circulatory survival and distal colonization from the perspectives of membrane lipid remodeling, energy homeostasis and signal transduction. The metabolic heterogeneity of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT)-like cells, as well as the metabolic reprogramming mediated by the target organ microenvironment, further enhance metastatic plasticity and organotropism. Interventional strategies targeting key molecules of fatty acid metabolism have shown promising anti-metastatic potential, providing a core research direction for subsequent precise metabolic targeted therapy against metastasis.